Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a Study of BMS-986242 Administered in Combination With Nivolumab (BMS-936558, Anti-PD-1) in Advanced Malignant Tumors

NCT03351231 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT03351231
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03351231 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a Study of BMS-986242 Administered in Combination With Nivolumab (BMS-936558, Anti-PD-1) in Advanced Malignant Tumors
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 1/2
Overall status
Terminated
Start date
November 27, 2017
Completion date
August 28, 2018
Enrollment
7 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cancer